Implants News and Research

RSS

Unique heart arrhythmia drug represents one of the first molecular-based therapies for heart failure

Heart researchers at Columbia University Medical Center have developed and tested a unique heart arrhythmia drug that could prevent the sudden death of millions of people with heart failure as well as people with an inherited heart disorder. The drug represents one of the first molecular-based therapies for heart failure and avoids the toxicity of current treatments.

8 Apr 2004

Lab discovers way to keep short-lived catalysts active for longer than five months

Enzymes, the workhorses of chemical reactions in cells, lead short and brutal lives. They cleave and assemble proteins and metabolize compounds for a few hours, and then they are spent. This sad fact of nature has limited the possibilities of harnessing enzymes as catalytic tools outside the cell, in uses that range from biosensing to toxic waste cleanup.

1 Apr 2004

Emerging technologies in tissue engineering and regenerative medicine analysis

Pathbreaking developments in tissue engineering and regenerative therapies are facilitating the design and growth of new organs in labs using biopolymer scaffolds and matrices. Analysis of potential markets for tissue engineering reveals that basic problems such as vascularity must be solved before such implants can gain acceptance as standard treatment methods.

30 Mar 2004

Carbon Dioxide may be used in medical implants

Carbon dioxide, an environmentally friendly solvent for dyeing and dry cleaning, may become a valuable new tool for making medical implants, according to a study at Ohio State University.

23 Mar 2004

Stem cell research that could help diabetics

University of Florida adult stem cell experts have restored normal blood sugar levels in diabetic mice for three months by chemically coaxing bone marrow cells to produce insulin, a hormone normally made in the pancreas.

22 Mar 2004

New resorbable beta-tricalcium phosphate bone void filler

Therics, Inc., a subsidiary of Tredegar Corporation, announced that it has received FDA clearance to market a new resorbable beta-tricalcium phosphate bone void filler device used to treat osseous defects of the skeletal system.

22 Mar 2004

New Treatment for Chronic Head Pain

Dr. Levy pioneered a procedure known as supraorbital nerve stimulation or SOS, in which neurotransmitters are implanted into the forehead to block head pain. Tiny wires are burrowed under the skin until the precise location of pain is marked by a tingling response to electrical charge. The wires are kept in place for a week, and if pain is lessened and the patient is comfortable with the technology, neurotransmitters are surgically implanted under local anesthesia. The patient is able to control pain relief by manually adjusting the level of electrical stimulation through a hand held device.

22 Mar 2004